These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

994 related articles for article (PubMed ID: 27880910)

  • 1. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
    Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI
    Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
    Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
    Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
    Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.
    Alagpulinsa DA; Ayyadevara S; Yaccoby S; Shmookler Reis RJ
    Mol Cancer Ther; 2016 Feb; 15(2):241-50. PubMed ID: 26719576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
    Quereda V; Bayle S; Vena F; Frydman SM; Monastyrskyi A; Roush WR; Duckett DR
    Cancer Cell; 2019 Nov; 36(5):545-558.e7. PubMed ID: 31668947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition.
    Xia Q; Cai Y; Peng R; Wu G; Shi Y; Jiang W
    Int J Oncol; 2014 Mar; 44(3):735-44. PubMed ID: 24378347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
    Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S
    Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
    Evans KW; Yuca E; Akcakanat A; Scott SM; Arango NP; Zheng X; Chen K; Tapia C; Tarco E; Eterovic AK; Black DM; Litton JK; Yap TA; Tripathy D; Mills GB; Meric-Bernstam F
    Clin Cancer Res; 2017 Nov; 23(21):6468-6477. PubMed ID: 29093017
    [No Abstract]   [Full Text] [Related]  

  • 12. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
    Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
    Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
    [No Abstract]   [Full Text] [Related]  

  • 14. Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition.
    Villamar Cruz O; Prudnikova TY; Araiza-Olivera D; Perez-Plasencia C; Johnson N; Bernhardy AJ; Slifker M; Renner C; Chernoff J; Arias-Romero LE
    Oncotarget; 2016 Nov; 7(47):76590-76603. PubMed ID: 27740936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
    Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
    Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer.
    Orhan E; Velazquez C; Tabet I; Fenou L; Rodier G; Orsetti B; Jacot W; Sardet C; Theillet C
    Cancer Lett; 2024 May; 589():216820. PubMed ID: 38574883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer.
    Wooten J; Mavingire N; Damar K; Loaiza-Perez A; Brantley E
    J Cell Physiol; 2023 Aug; 238(8):1625-1640. PubMed ID: 37042191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.
    Geenen JJJ; Linn SC; Beijnen JH; Schellens JHM
    Clin Pharmacokinet; 2018 Apr; 57(4):427-437. PubMed ID: 29063517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
    Lin ZP; Zhu YL; Lo YC; Moscarelli J; Xiong A; Korayem Y; Huang PH; Giri S; LoRusso P; Ratner ES
    PLoS One; 2018; 13(11):e0207399. PubMed ID: 30444904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
    Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
    Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.